b56-prostate-cancer-programme

What problem does it solve?

This Skill provides a structured, clinician-facing framework to qualify patients, select appropriate therapies, and monitor outcomes for prostate cancer across stages (mHSPC, nmCRPC, mCRPC). It consolidates eligibility criteria, required diagnostics, treatment durations, and exclusion criteria into a single, actionable guide that can be loaded into clinical decision support contexts.

Core Features & Use Cases

• Programme scope: Defines approved drugs and combinations for each disease stage, with explicit eligibility and monitoring requirements.
• Guidance for clinicians: Assists in patient qualification, drug selection, dosing, monitoring, and follow-up per the B.56 programme.
• Use Case: A clinician uses the guideline to determine if a patient with metastatic hormone-sensitive prostate cancer qualifies for darolutamide+docetelaxel vs apalutamide alone, and to plan required diagnostics and follow-up.

Quick Start

Use the B.56 Programme to verify patient eligibility and outline the diagnostic and monitoring steps before initiating therapy.